Clinical Trials Logo

Uterine Cervical Neoplasms clinical trials

View clinical trials related to Uterine Cervical Neoplasms.

Filter by:

NCT ID: NCT06238635 Recruiting - Cervical Cancer Clinical Trials

Dostarlimab and Cobolimab in Advanced Cervical Cancer

Start date: March 11, 2024
Phase: Phase 2
Study type: Interventional

This research is being done to determine how effective dostarlimab in combination with cobolimab is in metastatic or recurrent cervical cancer.

NCT ID: NCT06237257 Recruiting - Clinical trials for Locally Advanced Cervical Cancer

A Study of Chemoradiotherapy With SHR-1316 For Treatment of Locally Advanced Cervical Cancer

Start date: March 20, 2024
Phase: Phase 2
Study type: Interventional

The Primary purpose of this study is to evaluate the safety of SHR-1316 plus concurrent chemoradiotherapy in participants with locally advanced cervical cancer. The second purpose of this study is to evaluate the efficacy and PK traits; The exploratory study is to explore the biomarker 、immunogenicity and so on .

NCT ID: NCT06232083 Recruiting - Immunotherapy Clinical Trials

Application of PLDR External Irradiation Combined With Immune Checkpoint Inhibitors in Recurrent Cervical Cancer

Start date: February 1, 2024
Phase: Phase 1/Phase 2
Study type: Interventional

At present, the treatment methods for recurrent cervical cancer are very limited. The immune checkpoint inhibitors (ICBs) is a promising new directions for recurrent cervical cancer, but the clinical response rate is insufficient. Pulse low-dose rate radiotherapy (PLDR) is a new technology in recent years, which uses continuous pulse low-dose rate irradiation to induce hypersensitivity in tumors, and its clinical safety has been verified. Compared to conventional radiotherapy, PLDR has advantages in protecting the lymphatic system and relieving the immune barrier, but it is still unclear whether it can improve the efficacy of ICB. This project aims to combine PLDR with ICB to explore new strategies for recurrent cervical cancer.

NCT ID: NCT06223308 Recruiting - Cervical Cancer Clinical Trials

A Study Evaluating the Safety and Efficacy of HB0028 in Subjects With Advanced Solid Tumors

Start date: September 9, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

It is a phase I/II open label, multicenter study to assess the safety, tolerability, pharmacokinetics, and efficacy of HB0028 in patients with advanced solid tumors.

NCT ID: NCT06215950 Recruiting - Ovarian Cancer Clinical Trials

A Clinical Research About CD70-targeted CAR-T in the Treatment of CD70-positive Advanced/Metastatic Gynecologic Cancer

Start date: January 10, 2024
Phase: Phase 1
Study type: Interventional

This is a single-center, double-arm, open-label study. this study plans to evaluate the safety and efficacy of CD70-targeting CAR-T cells in the treatment of CD70-positive advanced/metastatic Gynecologic Cancer, and obtain recommended doses and infusion patterns.

NCT ID: NCT06209294 Recruiting - Cervical Cancer Clinical Trials

Phase II Study on Neoadjuvant Therapy of AK104 Combined With Nab-paclitaxel/Carboplatin in Fertility Preserving Surgery

Start date: September 1, 2023
Phase: Phase 2
Study type: Interventional

This is a Phase II study of neoadjuvant therapy of AK104 combined with nab-paclitaxel/carboplatin in fertility saving surgery for stage IB2-IB3 cervical cancer (FIGO 2018). The main questions it aims to answer are: - · Evaluate the safety of AK104 combined with nab-paclitaxel/carboplatin in the neoadjuvant treatment of cervical cancer - · Evaluate the tumor regression and Major Pathological Response(MPR) of AK104 combined with nab-paclitaxel/carboplatin as neoadjuvant therapy for cervical cancer.

NCT ID: NCT06204133 Recruiting - Clinical trials for Artificial Intelligence

Model Study on Cervical Cancer Screening Strategies and Risk Prediction

Start date: November 1, 2023
Phase:
Study type: Observational

By collecting non-image medical data of women undergoing cervical screening in multiple centers in China, including age, HPV infection status, HPV infection type, TCT results, and colposcopy biopsy pathology results, a multi-source heterogeneous cervical lesion collaborative research big data platform was established. Based on artificial intelligence (AI) machine learning, cervical lesion screening features are refined, a multi-modal cervical cancer intelligent screening prediction and risk triage model is constructed, and its clinical application value is preliminarily explored.

NCT ID: NCT06203106 Recruiting - Clinical trials for Diabetes Mellitus, Type 2

NYSCF Scientific Discovery Biobank

Start date: November 10, 2022
Phase:
Study type: Observational

The New York Stem Cell Foundation (NYSCF) Research Institute is performing this research to accelerate diverse disease research using cells from the body (such as skin or blood cells) to make stem cells and other types of cells, conduct research on the samples, perform genetic testing, and store the samples for future use. Through this research, researchers hope to identify future treatments or even cures for the major diseases of our time.

NCT ID: NCT06196190 Recruiting - Cervix Cancer Clinical Trials

Prognostic Value of Conization and Negative HPV After Conization in AIS and Early Stage Cervical Cancer

Start date: July 26, 2023
Phase:
Study type: Observational

In women with cervical cancer -Squamous cell carcinoma, Adeno carcinoma, Adeno-squamous carcinoma or AIS we want to examine prospectively: 1. Examine if negative HR-HPV after conization to the HR-HPV the women had before conization has a high prognostic value for no residual tumor in the final pathology. 2. To examine if conization in women with cervical tumor up to Stage I B 2 (FIGO 2018) is corelated with better prognosis.

NCT ID: NCT06191900 Recruiting - Adult Clinical Trials

Clinical Study of GT201 in the Treatment of Advanced Gynecological Tumors (Advanced Cervical Cancer)

Start date: June 5, 2023
Phase: N/A
Study type: Interventional

This study is an early exploration clinical study with one arm. The study consists of two stages, namely the dose escalation stage and the dose extension stage: